{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-ddpCreated=2014-10-23T20%3A01%3A22.130Z&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&min-ddpModified.=2015-02-08T12%3A59%3A17.343Z&writtenParliamentaryQuestionType=Ordinary&max-answer.dateOfAnswer=2019-05-17", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-ddpCreated=2014-10-23T20%3A01%3A22.130Z&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&min-ddpModified.=2015-02-08T12%3A59%3A17.343Z&writtenParliamentaryQuestionType=Ordinary&max-answer.dateOfAnswer=2019-05-17", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-ddpCreated=2014-10-23T20%3A01%3A22.130Z&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&_metadata=all&min-ddpModified.=2015-02-08T12%3A59%3A17.343Z&writtenParliamentaryQuestionType=Ordinary&max-answer.dateOfAnswer=2019-05-17", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-ddpCreated=2014-10-23T20%3A01%3A22.130Z&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&min-ddpModified.=2015-02-08T12%3A59%3A17.343Z&writtenParliamentaryQuestionType=Ordinary&max-answer.dateOfAnswer=2019-05-17", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-ddpCreated=2014-10-23T20%3A01%3A22.130Z&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&min-ddpModified.=2015-02-08T12%3A59%3A17.343Z&writtenParliamentaryQuestionType=Ordinary&max-answer.dateOfAnswer=2019-05-17", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-ddpCreated=2014-10-23T20%3A01%3A22.130Z&max-questionFirstMinisteriallyCorrected.=2014-12-10T16%3A29%3A44.707Z&min-ddpModified.=2015-02-08T12%3A59%3A17.343Z&writtenParliamentaryQuestionType=Ordinary&max-answer.dateOfAnswer=2019-05-17", "items" : [{"_about" : "http://data.parliament.uk/resources/167082", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/167082/answer", "answerText" : {"_value" : "

There are an estimated 250,000 people with the<\/ins> sickle cell trait<\/ins> anaemia<\/del> in the United Kingdom. The Department has made no estimation of the annual cost of treating sickle cell anaemia in the National Health Service nor does it hold information on the total NHS spend on sickle cell anaemia.<\/p>

<\/p>

<\/p>

<\/p>

The Department does hold estimated costs for admitted patient care episodes as reported by Healthcare Resource Groups. In 2013-14 the total estimated figure for sickle anaemia was £23.8 million; in 2012-13 it was £21.9 million. This figure does not include other costs such as primary and social care.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"} } , "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} , "dateOfAnswer" : {"_value" : "2014-12-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/167082/answer/previousversion/32239", "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"} } , "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} } , "questionFirstAnswered" : [{"_value" : "2014-12-08T15:12:22.81Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-12-10T16:29:44.707Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-12-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Sickle Cell Diseases"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the annual cost to the NHS of treating sickle cell anaemia.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1587", "label" : {"_value" : "Biography information for Pat McFadden"} } , "tablingMemberConstituency" : {"_value" : "Wolverhampton South East"} , "tablingMemberPrinted" : [{"_value" : "Mr Pat McFadden"} ], "uin" : "216529"} , {"_about" : "http://data.parliament.uk/resources/100721", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100721/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100721/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Osteoporosis"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211732"} , {"_about" : "http://data.parliament.uk/resources/100723", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100723/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100723/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Motor Neurone Disease: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211734"} , {"_about" : "http://data.parliament.uk/resources/100728", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100728/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100728/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Motor Neurone Disease"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on research into motor neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211730"} , {"_about" : "http://data.parliament.uk/resources/100730", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100730/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100730/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Osteoporosis: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to treat symptoms of osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211735"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 5, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }